Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy or ABVD + Radiotherapy vs ABVD Alone in Early Stage Hodgkin's Disease
NCT00002561Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 1994
- Primary completion
- Aug 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine and dacarbazine in Hodgkin lymphoma (HL) (4 cohorts), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall Survival at 12 years. Started Jan 1994; status: completed.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00002561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002561.